J3370 is terminated (historical record)
Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J3370
500 MG
No published MUE for J3370. CMS keeps some MUE values confidential, so this does not mean there is no daily unit limit.
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Most recent Medicare Part B payment limit · Q2 2025
$1.949per 500 MG
Effective Apr 1, 2025 – Jun 30, 2025 · ASP methodology (per CMS file) · based on Q4 2024 ASP data · coinsurance 20.000%
Not in the latest payment limit file (Q4 2026). Shown for history only.
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.949 | 500 MG | 20% | +4.6% | — |
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $1.863 | 500 MG | 20% | −13.9% |
Medicare hospital outpatient (OPPS)
No authoritative public data was located for this field.
Washington Apple Health · professional claims
Not on HCA's professional administered drug fee schedule.
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
No CMS NDC–HCPCS crosswalk rows were located. CMS notes its crosswalks are not a comprehensive list of all NDCs.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 47781-0597-91 | Vancomycin HClALVOGEN | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 47781-0598-91 | Vancomycin HClALVOGEN | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q3 2024Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 72611-0765-10 | Vancomycin HClAlvogen, Inc. | 1 × 10 | 2 | 20 | ASP | Q1 2022 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 68001-0338-62 | Vancomycin HClAMERICAN HEALTH PACKAGING | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 68001-0339-64 | Vancomycin HClAMERICAN HEALTH PACKAGING | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 68001-0406-73 | Vancomycin HClAMERICAN HEALTH PACKAGING | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 70860-0104-10 | Vancomycin HClAthenex Pharmaceutical Division, LLC | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 70860-0105-20 | Vancomycin HClAthenex Pharmaceutical Division, LLC | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 55150-0204-20 | Vancomycin HClAUROMEDICS PHARMA LLC | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-0122-04 | Vancomycin HClBaxter Healthcare Corporation | 250 × 4 | 2.5 | 10 | ASP | Q4 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-0124-04 | Vancomycin HClBaxter Healthcare Corporation | 300 × 4 | 3 | 12 | ASP | Q4 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-3551-48 | Vancomycin HClBaxter Healthcare Corporation | 100 × 1 | 1 | 1 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-3552-48 | Vancomycin HClBaxter Healthcare Corporation | 200 × 1 | 2 | 2 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-3580-48 | Vancomycin HClBaxter Healthcare Corporation | 150 × 1 | 1.5 | 1.5 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-3581-01 | Vancomycin HClBaxter Healthcare Corporation | 100 × 1 | 1 | 1 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-3582-01 | Vancomycin HClBaxter Healthcare Corporation | 150 × 1 | 1.5 | 1.5 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00338-3583-01 | Vancomycin HClBaxter Healthcare Corporation | 200 × 1 | 2 | 2 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 68001-0407-75 | Vancomycin HClBluePoint Laboratories | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 68001-0465-62 | Vancomycin HClBLUEPOINT LABORATORIES | 1 × 10 | 1 | 10 | ASP | Q1 2024 – Q2 2024Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 51991-0940-17 | Vancomycin HClBRECKENRIDGE PHARMACEUTICAL | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 51991-0941-17 | Vancomycin HClBRECKENRIDGE PHARMACEUTICAL | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 72572-0801-02 | Vancomycin HClCivica, Inc. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 72572-0803-01 | Vancomycin HClCivica, Inc. | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 72572-0805-01 | Vancomycin HClCivica, Inc. | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 55150-0471-10 | Vancomycin HClEugia US LLC | 1 × 10 | 2.5 | 25 | ASP | Q1 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 55150-0472-10 | Vancomycin HClEugia US LLC | 1 × 10 | 3 | 30 | ASP | Q1 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0221-38 | Vancomycin HClFRESENIUS KABI | 1 × 25 | 1 | 25 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0221-48 | Vancomycin HClFRESENIUS KABI | 1 × 25 | 1 | 25 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0284-21 | Vancomycin HClFRESENIUS KABI | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0284-45 | Vancomycin HclFRESENIUS KABI | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0314-68 | Vancomycin HclFRESENIUS KABI | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0203-20 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 1.5 | 15 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0203-26 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 1.5 | 15 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0221-10 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 25 | 1 | 25 | ASP | Q1 2022 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0221-16 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 25 | 1 | 25 | ASP | Q1 2022 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0284-20 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0284-26 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 10 | 2 | 20 | ASP | Q2 2022 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0295-61 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0295-66 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0314-61 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 63323-0314-66 | Vancomycin HClFreseniUS Kabi USA, LLC | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00404-9965-99 | Vancomycin HClHenry Schein Inc. | 1 × 1 | 1 | 1 | ASP | Q3 2023 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00143-9152-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 2.5 | 25 | ASP | Q1 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00143-9153-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 3 | 30 | ASP | Q1 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00143-9355-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 1.5 | 15 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00143-9357-10 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 10 | 2 | 20 | ASP | Q1 2023 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00143-9358-01 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00143-9359-01 | Vancomycin HClHikma Pharmaceuticals USA Inc. | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 71288-0024-21 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 10 | 1.5 | 15 | ASP | Q2 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 71288-0025-75 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 1 | 10 | 10 | ASP | Q2 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 71288-0026-75 | Vancomycin HClMeitheal Pharmaceuticals Inc. | 1 × 1 | 20 | 20 | ASP | Q3 2023 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 71288-0022-11 | Vancomycin HClMEITHEAL PHARMACEUTICALS, INC. | 1 × 10 | 1 | 10 | ASP | Q4 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 71288-0023-21 | Vancomycin HClMEITHEAL PHARMACEUTICALS, INC. | 1 × 10 | 2 | 20 | ASP | Q4 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 67457-0339-50 | Vancomycin HClMylan Institutional LLC | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 67457-0340-01 | Vancomycin HClMylan Institutional LLC | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 67457-0341-05 | Vancomycin HClMylan Institutional LLC | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 67457-0342-10 | Vancomycin HClMylan Institutional LLC | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 67457-0611-10 | Vancomycin HClMYLAN INSTITUTIONAL LLC | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 67457-0612-20 | Vancomycin HClMYLAN INSTITUTIONAL LLC | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 67457-0613-10 | Vancomycin HClMYLAN INSTITUTIONAL LLC | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 67457-0614-10 | Vancomycin HclMYLAN INSTITUTIONAL LLC | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 67457-0705-75 | Vancomycin HclMYLAN INSTITUTIONAL LLC | 1 × 10 | 1.5 | 15 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 67457-0822-99 | Vancomycin HClMYLAN INSTITUTIONAL LLC | 1 × 10 | 0.5 | 5 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 67457-0823-99 | Vancomycin HClMYLAN INSTITUTIONAL LLC | 1 × 10 | 2.5 | 25 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 67457-0824-99 | Vancomycin HClMYLAN INSTITUTIONAL LLC | 1 × 10 | 3 | 30 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 16714-0247-10 | Vancomycin HClNorthstar RxLLC | 1 × 10 | 1 | 10 | ASP | Q1 2023 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 16714-0309-10 | Vancomycin HClNorthstar RxLLC | 1 × 10 | 2 | 20 | ASP | Q1 2023 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 00409-1319-01 | Vancomycin HClPfizer Inc | 1 × 1 | 20 | 20 | ASP | Q3 2022 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-3515-01 | Vancomycin HClPfizer Inc | 1 × 10 | 3 | 30 | ASP | Q4 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-4332-01 | Vancomycin HClPfizer Inc | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-5017-01 | Vancomycin HClPfizer Inc | 1 × 1 | 20 | 20 | ASP | Q2 2023 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 00409-6509-01 | Vancomycin HClPfizer Inc | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-6509-49 | Vancomycin HClPfizer Inc | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-6531-01 | Vancomycin HClPfizer Inc | 1 × 10 | 1.5 | 15 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 00409-6531-02 | Vancomycin HClPfizer Inc | 1 × 10 | 1.5 | 15 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-6533-21 | Vancomycin HClPfizer Inc | 1 × 10 | 2 | 20 | ASP | Q4 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-6533-31 | Vancomycin HClPfizer Inc | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 00409-6534-01 | Vancomycin HClPfizer Inc | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 00409-6535-01 | Vancomycin HClPfizer Inc | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 00409-6510-01 | Vancomycin HClPFIZER INC. | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 00409-6533-01 | Vancomycin HclPFIZER INC. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 25021-0150-10 | Vancomycin HClSagent Pharmaceuticals | 1 × 10 | 1 | 10 | ASP | Q1 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 25021-0151-20 | Vancomycin HClSagent Pharmaceuticals | 1 × 10 | 2 | 20 | ASP | Q1 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 25021-0157-99 | Vancomycin HClSagent Pharmaceuticals | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin |
| 25021-0158-99 | Vancomycin HClSagent Pharmaceuticals | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin |
| 70436-0020-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 70436-0021-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 10 | 2 | 20 | ASP | Q2 2021 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 70436-0022-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 1 | 10 | 10 | ASP | Q3 2022 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 70436-0023-82 | Vancomycin HClSlate Run Pharmaceuticals | 1 × 1 | 20 | 20 | ASP | Q3 2022 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 70594-0041-03 | Vancomycin HclXELLIA PHARMACEUTICALS USA, LLC | 100 × 12 | 1 | 12 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin |
| 70594-0042-03 | Vancomycin HClXELLIA PHARMACEUTICALS USA, LLC | 1 × 12 | 2 | 24 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin |
| 70594-0043-02 | Vancomycin HClXELLIA PHARMACEUTICALS USA, LLC | 1 × 6 | 3 | 18 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin |
| 70594-0044-02 | VancomycinXELLIA PHARMACEUTICALS USA, LLC | 400 × 6 | 4 | 24 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin |
| 70594-0056-03 | Vancomycin HClXELLIA PHARMACEUTICALS USA, LLC | 150 × 12 | 1.5 | 18 | ASP | Q2 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin |
| 70594-0057-02 | Vancomycin HydrochlorideXELLIA PHARMACEUTICALS USA, LLC | 250 × 6 | 2.5 | 15 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin |
| 70594-0058-02 | Vancomycin HydrochlorideXELLIA PHARMACEUTICALS USA, LLC | 350 × 6 | 3.5 | 21 | ASP | Q2 2021 – Q4 2022Not in Q4 2026 file | ListedVancomycin |
| 70594-0045-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 1 | 10 | ASP | Q3 2022 – Q2 2025Not in Q4 2026 file | Not found |
| 70594-0046-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 70594-0047-01 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 1 | 10 | 10 | ASP | Q3 2022 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 70594-0048-01 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | Excluded listingVancomycin Hydrochloride |
| 70594-0122-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 1 | 10 | ASP | Q4 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
| 70594-0123-02 | Vancomycin HClXellia Pharmaceuticals USA, LLC. | 1 × 10 | 2 | 20 | ASP | Q4 2024 – Q2 2025Not in Q4 2026 file | ListedVancomycin Hydrochloride |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q3 2025 | Termination date set | D — Discontinued | Termination date Jun 30, 2025 |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1986 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| — |
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $2.164 | 500 MG | 20% | +8.5% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $1.995 | 500 MG | 20% | −22.6% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $2.578 | 500 MG | 20% | +11.7% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $2.307 | 500 MG | 20% | +10.6% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $2.086 | 500 MG | 20% | −13.4% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $2.409 | 500 MG | 20% | −3.1% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $2.486 | 500 MG | 20% | −13.0% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $2.856 | 500 MG | — | −11.6% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $3.232 | 500 MG | — | +9.3% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $2.958 | 500 MG | — | +8.1% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $2.736 | 500 MG | — | −1.4% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $2.776 | 500 MG | — | −2.3% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $2.842 | 500 MG | — | +11.9% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $2.539 | 500 MG | — | −13.3% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $2.928 | 500 MG | — | +12.0% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $2.614 | 500 MG | — | — | — |
|---|